Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Lenz: focused on an eye drop for age-related farsightedness

Emerging Company Profile: With Versant, RA Capital-backed $47M series A, Lenz eyes pivotal study for presbyopia program

By Paul Bonanos, Associate Editor
June 17, 2021 3:08 PM UTC

Lenz is well-financed to begin a pivotal study of a pupil-contracting eye drop addressing the largest market in ophthalmology: presbyopia, or age-related farsightedness.

Backed by Versant Ventures and RA Capital, newly rechristened Lenz Therapeutics Inc. will advance a formulation of AChE receptor agonist aceclidine that has been shown to improve near vision in a Phase II trial...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Lenz Therapeutics Inc.